CA3127590A1 - Mitofusin activators and methods of use thereof - Google Patents

Mitofusin activators and methods of use thereof Download PDF

Info

Publication number
CA3127590A1
CA3127590A1 CA3127590A CA3127590A CA3127590A1 CA 3127590 A1 CA3127590 A1 CA 3127590A1 CA 3127590 A CA3127590 A CA 3127590A CA 3127590 A CA3127590 A CA 3127590A CA 3127590 A1 CA3127590 A1 CA 3127590A1
Authority
CA
Canada
Prior art keywords
cycloalkyl
alkyl
disease
mitochondrial
mitofusin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3127590A
Other languages
English (en)
French (fr)
Inventor
Gerald W. Ii Dorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitochondria Emotion Inc
Original Assignee
Mitochondria Emotion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitochondria Emotion Inc filed Critical Mitochondria Emotion Inc
Publication of CA3127590A1 publication Critical patent/CA3127590A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3127590A 2019-01-28 2019-08-13 Mitofusin activators and methods of use thereof Pending CA3127590A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797513P 2019-01-28 2019-01-28
US62/797,513 2019-01-28
PCT/US2019/046356 WO2020159576A1 (en) 2019-01-28 2019-08-13 Mitofusin activators and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3127590A1 true CA3127590A1 (en) 2020-08-06

Family

ID=71841603

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3127590A Pending CA3127590A1 (en) 2019-01-28 2019-08-13 Mitofusin activators and methods of use thereof

Country Status (6)

Country Link
US (4) US11141390B2 (enExample)
EP (1) EP3917508A4 (enExample)
JP (1) JP7473565B2 (enExample)
AU (1) AU2019427489B2 (enExample)
CA (1) CA3127590A1 (enExample)
WO (1) WO2020159576A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018200323A1 (en) * 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12440481B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
JP7734917B2 (ja) * 2019-01-28 2025-09-08 ミトコンドリア エモーション， インク． トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
KR20230159470A (ko) 2021-03-19 2023-11-21 미토콘드리아 이모션, 인크. N-(트랜스-4-하이드록시시클로헥실)-6-페닐헥산아미드 및 관련 화합물의 시클로프로판 유사체
WO2022204125A1 (en) 2021-03-22 2022-09-29 Mitochondria Emotion, Inc. Polymorphic forms of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
US20250091983A1 (en) 2021-08-03 2025-03-20 Mitochondria Emotion, Inc. Cyclopentane and cyclohexane variants of 6-phenylhexanamide mitofusin activators and methods for use thereof
AU2023249138A1 (en) * 2022-04-06 2024-11-14 Gerald W. DORN II Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof
WO2024211432A1 (en) * 2023-04-03 2024-10-10 Mitochondria In Motion, Inc. N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives and related uses

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3184509A (en) * 1962-07-23 1965-05-18 Lilly Co Eli Derivatives of cyclopropanecarboxamide
US4466977A (en) 1981-04-09 1984-08-21 The Upjohn Company N-[2-Amino(oxy- or thia- group-substituted-cycloaliphatic)]benzeneacetamides and -benzamide analgesics
US4438130A (en) 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
US4463013A (en) 1982-04-09 1984-07-31 The Upjohn Company Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4588591A (en) 1984-05-25 1986-05-13 The Upjohn Company Analgesic 2-oxa-spirocyclic compounds
US4632935A (en) 1984-05-30 1986-12-30 The Upjohn Company Omega-(hydroxy-, ether and ester)-alkyl-2-amino-cycloalkyl- and cycloalkenyl amides as analgesics
US4618621A (en) 1984-09-21 1986-10-21 The Upjohn Company Method for treating medical conditions involving cerebral ischemia
US4677122A (en) 1984-11-13 1987-06-30 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4737493A (en) 1985-07-01 1988-04-12 Warner-Lambert Company 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro(4,5)decanes as analgesic agents
US4801604A (en) 1985-10-25 1989-01-31 The Upjohn Company Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants
IL83163A (en) * 1986-07-18 1991-06-10 Erba Carlo Spa Cycloalkyl-substituted 4-pyridyl derivatives,their preparation and pharmaceutical compositions containing them
FR2617164B1 (fr) 1987-06-25 1989-11-10 Roussel Uclaf Nouveaux derives de la decahydroquinoleine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US4855316A (en) 1988-02-18 1989-08-08 Warner-Lambert Company 1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
US5051428A (en) 1988-12-06 1991-09-24 Warner-Lambert Company 2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
US5063242A (en) 1989-04-21 1991-11-05 Warner-Lambert Company 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents
JP2532299B2 (ja) * 1989-10-06 1996-09-11 富士レビオ株式会社 パントテン酸誘導体
US5366987A (en) 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
FR2734815B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes arylalkyl (thio) carboxamides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US8815951B2 (en) * 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
US6531506B1 (en) * 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US6127159A (en) 1997-06-06 2000-10-03 The Board Of Trustees Of The Leland Stanford Junior University Mitofusin genes and their uses
EP1261340B1 (en) * 1999-07-13 2009-05-13 Alpha Research Group, LLC Compositions and methods for the treatment of parkinson's disease
AU8003400A (en) 1999-10-06 2001-05-10 Ansgar H. Santel Mitofusins, fzo homologs and functional derivatives thereof
AU2003303042A1 (en) 2002-12-17 2004-07-09 Pfizer Inc. 2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists
WO2004074482A1 (es) 2003-02-21 2004-09-02 Universidad De Barcelona Método de diagnóstico para diabetes y obesidad
JP4675330B2 (ja) 2003-11-14 2011-04-20 デューク ユニバーシティ シャルコー・マリー・ツース病２ａ型の検出方法
JP2008517072A (ja) 2004-10-20 2008-05-22 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良された阻害剤
US8226928B1 (en) 2011-06-17 2012-07-24 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8791069B1 (en) 2005-01-04 2014-07-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8354094B1 (en) 2005-01-04 2013-01-15 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8574544B1 (en) 2005-01-04 2013-11-05 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8361439B1 (en) 2005-01-04 2013-01-29 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
TWI385164B (zh) 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
US20100047177A1 (en) 2007-01-26 2010-02-25 Washington University Methods and compositions for treating neuropathies
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
WO2009114700A2 (en) 2008-03-12 2009-09-17 The Trustees Of Columbia University In The City Of New York Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion
US20110256565A1 (en) 2008-05-30 2011-10-20 Schon Eric A Methods for diagnosis and treatment of neurodegenerative diseases or disorders
US20110275670A1 (en) 2008-06-04 2011-11-10 Emma Chapman New Compounds VII
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
WO2011053825A2 (en) 2009-10-30 2011-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment or prevention of mitochondrial diseases
EP2504311B1 (en) 2009-11-25 2015-08-12 Cytometix, Inc. Arachidonic acid analogs and methods for analgesic treatment using same
WO2011133879A2 (en) 2010-04-22 2011-10-27 University Of Massachusetts Combination therapies with mitochondrial-targeted anti-tumor agents
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
PH12022550598A1 (en) 2010-12-23 2024-03-11 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012158624A2 (en) 2011-05-13 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of mitochondrial fission and methods of use thereof
WO2013010003A1 (en) 2011-07-12 2013-01-17 University Of Medicine And Dentistry Of New Jersey Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
WO2013123305A1 (en) 2012-02-16 2013-08-22 The Penn State Research Foundation Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
HRP20170532T4 (hr) 2012-07-12 2019-12-27 Khondrion Ip B.V. Derivati kromanila za liječenje mitohondrijske bolesti
US20160030517A1 (en) 2012-10-10 2016-02-04 University Of Washington Through Its Center For Commercialization Compositions and methods for diagnosis and treatment of neurological disease
US9603890B2 (en) 2012-12-03 2017-03-28 Vascular Biosciences Methods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
EP3043810B1 (en) 2013-09-09 2019-10-23 CanImGuide Therapeutics AB Immune system modulators
US20150168379A1 (en) 2013-12-12 2015-06-18 Macau University Of Science And Technology Method of identifying and screening drug candidate for preventing and/or treating ischemic myocardial disease
CN106061497A (zh) 2013-12-20 2016-10-26 曼尼托巴大学 用于治疗周围神经病变的方法和组合物
EP3108257B1 (en) 2014-02-17 2019-10-30 Société des Produits Nestlé S.A. Methods and uses of mitofusins
WO2015142001A2 (ko) * 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
KR101922542B1 (ko) 2014-03-21 2018-11-28 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
JP6659571B2 (ja) 2014-04-16 2020-03-04 ノーザン・シドニー・ローカル・ヘルス・ディストリクト 神経変性障害の治療又は予防のための細胞内Ｎｉｘ介在性マイトファジーを増大させる剤及び方法並びにキット
US10059748B2 (en) 2014-06-10 2018-08-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
US20180085391A1 (en) 2014-08-08 2018-03-29 Modernatx, Inc. Compositions and methods for the treatment of ophthalmic diseases and conditions
CA2958585C (en) 2014-08-21 2024-01-09 Stealth Biotherapeutics Corp Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
WO2016054083A1 (en) 2014-09-30 2016-04-07 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis
US9865522B2 (en) 2014-11-18 2018-01-09 International Business Machines Corporation Composite heat sink structures
KR101647030B1 (ko) 2014-11-20 2016-08-09 한국생명공학연구원 미토푸신 억제제를 포함하는, 세포 리프로그래밍 촉진용 조성물 및 이의 용도
WO2016115632A1 (en) 2015-01-21 2016-07-28 Exerkine Corporation Method for treating mitochondrial disease
WO2016126707A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US10143719B2 (en) 2015-02-06 2018-12-04 Case Western Reserve University Inhibitors of valosin-containing protein and methods of use
WO2016161294A1 (en) 2015-04-02 2016-10-06 Salk Institute For Biological Studies Err alpha and err gamma are essential coordinators of cardiac metabolism and function
WO2016205193A1 (en) 2015-06-15 2016-12-22 Rush Unversity Medical Center BRAIN DERIVED PPARα LIGANDS
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
CN108476164B (zh) 2015-12-21 2021-10-08 谷歌有限责任公司 在消息传送应用中自动地提供机器人服务的方法
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
WO2018013811A1 (en) 2016-07-14 2018-01-18 The Regents Of The University Of California Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
US11401255B2 (en) 2016-07-28 2022-08-02 Mayo Foundation For Medical Education And Research Small molecule activators of Parkin enzyme function
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
KR101872105B1 (ko) 2016-09-05 2018-06-27 사회복지법인 삼성생명공익재단 샤르코 마리 투스병 치료용 약학 조성물
KR20160108281A (ko) * 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2018057648A1 (en) * 2016-09-20 2018-03-29 The Board Of Trustees Of The Leland Stanford Junior University Peptide regulators of mitochondrial fusion and methods of use
WO2018098484A1 (en) 2016-11-28 2018-05-31 Texas Tech University System Drug targets of delayed aging and human brain diseases
EP3548039B1 (en) 2016-12-04 2023-07-19 Alavi Khorassani Moghadam, Marcel Victor Ribavirin for use in the treatment of a mitochondrial disease
CN120136858A (zh) 2017-03-31 2025-06-13 中美博瑞纳制药有限公司 可用作alcat1抑制剂的化合物
US20200054718A1 (en) 2017-04-05 2020-02-20 Lara S Milane EGFR/MFN2 Targeted Nanoparticles Particularly Useful For Treating Multidrug Resistant Triple Negative Breast Cancer Through Mitochondrial Fusion Inhibition
WO2018200323A1 (en) 2017-04-23 2018-11-01 Washington University Small molecule regulators of mitochondrial fusion and methods of use thereof
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
US20210128596A1 (en) 2017-09-27 2021-05-06 University Of Pennsylvania Compositions and methods for treating septic cardiomyopathy
EP3692169B1 (en) 2017-10-06 2023-08-16 Universiteit Antwerpen Biomarkers for charcot-marie-tooth type 2 disease
WO2019079243A1 (en) 2017-10-17 2019-04-25 Albert Einstein College Of Medicine, Inc. MITOFUSIN ACTIVATORS AND USES THEREOF
US10660873B2 (en) 2018-02-23 2020-05-26 University Of South Florida ALDA-1 treatment and prevention of pulmonary disease
CA3097840A1 (en) 2018-04-20 2019-10-24 Fondazione Telethon Mir-181 inhibitors and uses thereof
EP3575401A1 (en) 2018-05-29 2019-12-04 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of treating or preventing an aging-related disease
EP3801515B1 (en) 2018-06-06 2025-04-09 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
WO2020112565A1 (en) 2018-11-29 2020-06-04 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure

Also Published As

Publication number Publication date
WO2020159576A1 (en) 2020-08-06
EP3917508A1 (en) 2021-12-08
US12409157B2 (en) 2025-09-09
US11026904B2 (en) 2021-06-08
US20210251927A1 (en) 2021-08-19
US11141390B2 (en) 2021-10-12
JP2022518632A (ja) 2022-03-15
JP7473565B2 (ja) 2024-04-23
AU2019427489B2 (en) 2025-03-13
US20240082180A1 (en) 2024-03-14
AU2019427489A1 (en) 2021-07-22
EP3917508A4 (en) 2022-12-21
US20210046028A1 (en) 2021-02-18
US20200345669A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
AU2019427489B2 (en) Mitofusin activators and methods of use thereof
AU2020215510B2 (en) Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof
US10844023B2 (en) Small molecule regulators of mitochondrial fusion and methods of use thereof
WO2019122202A1 (en) Sting inhibitors
AU2019295632A1 (en) Taire family kinase inhibitors and uses thereof
WO2019094830A1 (en) Mitofusin modulation agents and methods of use thereof
US20240409528A1 (en) Binders of cereblon and methods of use thereof
AU2009330131B2 (en) Compounds and methods for the treatment of pain and other diseases
ES2693545T3 (es) Compuestos agonistas de GPR142
EP4075980B1 (en) Substituted 1,2, 4-triazoles and methods of use
US12396968B2 (en) Mitofusin activators having an endocyclic-bonded carbonyl group and methods for use thereof
US20240199534A1 (en) Cyclopropane analogues of n-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide and related compounds
WO2026044165A1 (en) Stereoisomeric fused-cyclopropyl analogues of 4-hydroxycyclohexane carboxamides and related compounds
EA048983B1 (ru) Циклопропановые аналоги n-(транс-4-гидроксициклогексил)-6-фенилгексанамида и родственных соединений

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240809

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240809

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240809

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240812

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241107

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241122

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250319

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250724

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250804

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250804

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250822

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20251222